High-frequency MRI monitoring should be performed in natalizumab-treated MS patients with higher risk of PML – YES

MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance

(2016) Martijn T Wijburg et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients

(2016) Mike P Wattjes et al.   Multiple Sclerosis Journal

Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging

(2016) Jérôme Hodel et al.   RADIOLOGY

Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients

(2016) Mike P Wattjes et al.   Multiple Sclerosis Journal

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

(2015)   Nature Reviews Neurology

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients

(2014) Tuan Dong-Si et al.   Annals of Clinical and Translational Neurology

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients

(2013) Stefanie Dahlhaus et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section

(2013) J. R. Berger et al.   NEUROLOGY

Classification of Natalizumab Cases with Progressive Multifocal Leukoencephalopathy (P07.058)

(2012) T. Dong-Si et al.   NEUROLOGY

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE